When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today

   www.aol.com/news/bio-path-holdings-news-why...

   These patients were using this method to treat acute myeloid leukemia instead of chemotherapy.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe update from Bio-Path Holdings shows ...

3. Bio-Path Holdings Announces Preclinical Testing of BP1001-A ...

   lite.aol.com/tech/story/0022/20241219/9321510.htm

   About Bio-Path Holdings, Inc. Bio-Path is a biotechnology company developing DNAbilize ®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood ...

4. Bio-Path Holdings Announces $4.0 Million Private Placement ...

   lite.aol.com/tech/story/0022/20241008/9253440.htm

   HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of ...

5. Bio-Path Holdings Initiates Development of Therapeutic ...

   lite.aol.com/tech/story/0022/20241008/9252494.htm

   HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the initiation of a therapeutic program to develop BP1001-A for the treatment of obesity and related metabolic diseases.

6. Nano-Cap Bio-Path Takes Plunge In Weight Loss Race ... - AOL

   www.aol.com/finance/nano-cap-bio-path-takes...

   Bio-Path Holdings, Inc., (NASDAQ:BPTH) stock is trading higher on Tuesday with a strong session volume of 25.89 million compared to an average of 328.97K as per data from Benzinga Pro. The company ...

7. We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash ...

   www.aol.com/news/were-keeping-eye-bio-path...

   For premium support please call: 800-290-4726 more ways to reach us

8. Bio-Path Holdings Outlines Rationale for Development of ...

   lite.aol.com/tech/story/0022/20241211/9317361.htm

   Bio-Path expects that by downregulating Grb2 expression, BP1001-A will lower blood glucose level by enhancing insulin-mediated AKT activation and glucose uptake and storage. Bio-Path is conducting preclinical studies to determine the effectiveness of BP1001-A in affecting insulin signaling and its potential as a therapeutic for obese patients ...

9. Here's Why We're Not Too Worried About Bio-Path Holdings ...

   www.aol.com/news/heres-why-were-not-too...

   For premium support please call: 800-290-4726 more ways to reach us